Inhibition of the MUC1-C oncoprotein induces multiple myeloma cell death by down-regulating TIGAR expression and depleting NADPH

MUC1-C oncoprotein suppresses reactive oxygen species-induced terminal differentiation of acute myelogenous leukemia cells

(2011) L. Yin et al.   BLOOD

Multiple Myeloma

(2011) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Downregulation of p53-inducible microRNAs 192, 194, and 215 Impairs the p53/MDM2 Autoregulatory Loop in Multiple Myeloma Development

(2010) Flavia Pichiorri et al.   CANCER CELL

Survival of Human Multiple Myeloma Cells Is Dependent on MUC1 C-Terminal Transmembrane Subunit Oncoprotein Function

(2010) L. Yin et al.   MOLECULAR PHARMACOLOGY

Inhibition of c-Met downregulates TIGAR expression and reduces NADPH production leading to cell death

(2010) V W Y Lui et al.   ONCOGENE

Schedule-dependent antitumor activity of the combination with erlotinib and docetaxel in human non-small cell lung cancer cells with EGFR mutation, KRAS mutation or both wild-type EGFR and KRAS

(2010) Furugaki   ONCOLOGY REPORTS

Direct Targeting of the Mucin 1 Oncoprotein Blocks Survival and Tumorigenicity of Human Breast Carcinoma Cells

(2009) D. Raina et al.   CANCER RESEARCH

HYD1-induced increase in reactive oxygen species leads to autophagy and necrotic cell death in multiple myeloma cells

(2009) R. R. Nair et al.   MOLECULAR CANCER THERAPEUTICS

MUC1 oncoprotein is a druggable target in human prostate cancer cells

(2009) M. D. Joshi et al.   MOLECULAR CANCER THERAPEUTICS